Investor acquires shares in Mölnlycke Health Care

August 26, 2010

Mölnlycke Health Care in short

- World leading supplier of single-use surgical and wound care products and services
- We invested together with Morgan Stanley Principal Investments (“MSPI”) in 2007
- Sales of EUR 865 m. and EBITDA of EUR 236 m. in 2009*
- Forecasted sales for 2010 of EUR ≈970 m., EBITDA EUR ≈270 m. and EBITA EUR ≈245 m.

*Refers to the regular calendar year, not with one month’s delay normally reported by Investor.

Investment rationale

A high-quality company in a growing global market

- Large and stable global industry with long-term sustainable growth
- Attractive platform for future growth
- Potential for further margin expansion
- Strong cash flow generation
- Strong management team with proven track record

Solid value creation



- New product introductions and more feet-in-the-street
- Operational excellence
- Investments in R&D footprint weigh on margins, but give platform for margin expansion



- Capital efficient business model gives strong cash conversion

Equity value creation

Today's transaction in brief

- Investor acquires 34 percent for a total cash consideration of EUR 510 m. (including acquisition of 4 percent in Q2)
  - Investor will own 96 percent
- Transaction values Mölnlycke at EUR 3.2 bn. (EV)
  - Implies 2010e multiples of 11.9x (EBITDA) and 13.1x (EBITA)
- Reported equity value to be based on the valuation of today's transaction in accordance with IFRS accounting
- Existing debt financing has no guarantees from Investor AB

investor

MÖLNLYCKE
HEALTH CARE

Our passion for progress will make us
the most trusted health care brand
in the world

Mölnlycke in a nutshell

MÖLNLYCKE HEALTH CARE
~ MEUR 865

WOUND CARE

40% OF SALES
60% OF EBITDA

SURGICAL

60% OF SALES
40% OF EBITDA

- Over 30 sales offices globally – sales in over 80 countries
- Manufacturing in 9 countries on 3 continents
- Over 6,700 employees globally

MÖLNLYCKE
HEALTH CARE

Strong products, strong positions

- Advanced Wound Care
  - #1 in Europe
  - #3 in the US
- Gloves
  - #1 globally
- Drapes & Gowns
  - #1 in Europe
- ProcedurePak
  - #1 in Europe

MÖLNLYCKE HEALTH CARE

Growing globally

	EMEA	AMERICAS	ASIA
			
% OF TOTAL	77%	19%	4%
SALES GROWTH	4%	19%	41%

Actions yielding results (2006 – 2010e)

- Increased R&D efforts
- More ”feet on the street”
- Value creating acquisitions

- Sales from MEUR 747 to MEUR 970
- U.S. market position from # 6 to # 2 or 3 in Wound Care
- Growth outpacing competitors
- Several products launches:
  - Mepitel One
  - Mepilex Ag
  - Antibacterial Platform
  - Avance
  - O.R. Efficiency
  - Bariatric Drape
- Promising product pipeline

MÖLNLYCKE HEALTH CARE

Financials 2006 - 2010 Forecast



- Net debt at acquisition
  - BEUR 1.96
- Net debt as of Q2 2010
  - BEUR 1.70
- Debt repayment over the period
  - MEUR 255
- 3-year average cash conversion
  - 83 %

MÖLNLYCKE HEALTH CARE

Sustaining our growth

- Strong innovation pipeline
- Acquisitions and licensing
- Geographic expansion
- Continue to address real health care challenges

MÖLNLYCKE HEALTH CARE

MÖLNLYCKE HEALTH CARE